JP2019512207A5 - - Google Patents

Download PDF

Info

Publication number
JP2019512207A5
JP2019512207A5 JP2018536458A JP2018536458A JP2019512207A5 JP 2019512207 A5 JP2019512207 A5 JP 2019512207A5 JP 2018536458 A JP2018536458 A JP 2018536458A JP 2018536458 A JP2018536458 A JP 2018536458A JP 2019512207 A5 JP2019512207 A5 JP 2019512207A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
variable region
chain variable
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018536458A
Other languages
English (en)
Japanese (ja)
Other versions
JP7022067B2 (ja
JP2019512207A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/013511 external-priority patent/WO2017124001A2/en
Publication of JP2019512207A publication Critical patent/JP2019512207A/ja
Publication of JP2019512207A5 publication Critical patent/JP2019512207A5/ja
Application granted granted Critical
Publication of JP7022067B2 publication Critical patent/JP7022067B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018536458A 2016-01-14 2017-01-13 Foxp3由来のペプチドに特異的なt細胞受容体様抗体 Expired - Fee Related JP7022067B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662278815P 2016-01-14 2016-01-14
US62/278,815 2016-01-14
PCT/US2017/013511 WO2017124001A2 (en) 2016-01-14 2017-01-13 T cell receptor-like antibodies specific for foxp3-derived peptides

Publications (3)

Publication Number Publication Date
JP2019512207A JP2019512207A (ja) 2019-05-16
JP2019512207A5 true JP2019512207A5 (cg-RX-API-DMAC7.html) 2020-02-20
JP7022067B2 JP7022067B2 (ja) 2022-02-17

Family

ID=59311684

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018536458A Expired - Fee Related JP7022067B2 (ja) 2016-01-14 2017-01-13 Foxp3由来のペプチドに特異的なt細胞受容体様抗体

Country Status (5)

Country Link
US (1) US11505599B2 (cg-RX-API-DMAC7.html)
EP (1) EP3402518A4 (cg-RX-API-DMAC7.html)
JP (1) JP7022067B2 (cg-RX-API-DMAC7.html)
CN (1) CN109069627A (cg-RX-API-DMAC7.html)
WO (1) WO2017124001A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180019725A (ko) * 2015-06-23 2018-02-26 메모리얼 슬로안-케터링 캔서 센터 신규의 피디 1 면역 조절제
CN107614519B (zh) 2015-10-23 2022-08-05 优瑞科生物技术公司 抗体/t细胞受体嵌合构建体及其用途
JP7538601B2 (ja) 2017-04-26 2024-08-22 ユーリカ セラピューティックス, インコーポレイテッド キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用
US20210147550A1 (en) * 2017-08-18 2021-05-20 Joshua Michael Francis Antigen-binding proteins targeting shared antigens
CN112041432A (zh) * 2018-02-15 2020-12-04 纪念斯隆-凯特林癌症中心 Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法
EP3954707A1 (en) * 2018-12-21 2022-02-16 Zhejiang Shimai Pharmaceutical Co., Ltd. Protease cleavable bispecific antibodies and uses thereof
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
WO2022221669A1 (en) * 2021-04-15 2022-10-20 Kyverna Therapeutics, Inc. Methods and compositions for treating disease using targeted foxp3+cd4+ t cells and cellular suicide agents
WO2024100170A1 (en) 2022-11-11 2024-05-16 F. Hoffmann-La Roche Ag Antibodies binding to hla-a*02/foxp3
EP4661902A1 (en) * 2023-02-06 2025-12-17 Memorial Sloan-Kettering Cancer Center Compositions including anti-wt-1 antibodies & antigen binding fragments and uses thereof
WO2025145063A1 (en) * 2023-12-29 2025-07-03 Eureka Therapeutics, Inc. Constructs targeting msln peptide/mhc complexes and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1975A (en) 1841-02-12 Manner of constructing corn-shellers
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
ATE374214T1 (de) * 2001-04-27 2007-10-15 Kirin Brewery Monoklonaler anti-cd-40-antikörper
US20100003253A1 (en) 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
EP3299393A1 (en) * 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US9320792B2 (en) * 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
DK1749029T3 (da) 2004-05-27 2011-06-06 Crucell Holland Bv Bindemolekyler, der kan neutralisere rabiesvirus, og anvendelser deraf
JP4829609B2 (ja) * 2004-12-22 2011-12-07 独立行政法人科学技術振興機構 ヒト抗体酵素およびその生産方法
WO2007025388A2 (en) 2005-09-01 2007-03-08 National Research Council Of Canada Anti-apoptotic protein antibodies
EP2064350B1 (en) * 2006-11-27 2013-01-02 Ludwig Institute for Cancer Research Ltd. Expression of foxp3 by cancer cells
TWI441648B (zh) * 2007-01-03 2014-06-21 Oncotherapy Science Inc Foxp3胜肽疫苗
WO2009003489A1 (en) 2007-07-02 2009-01-08 Natimmune A/S CaOU-1 EPITOPE BINDING POLYPEPTIDES
EP2020419A1 (en) * 2007-07-31 2009-02-04 Bayer Schering Pharma Aktiengesellschaft Anti ephB4 antibody fragments
WO2009079259A2 (en) * 2007-12-06 2009-06-25 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
JP5432727B2 (ja) 2008-01-29 2014-03-05 株式会社抗体研究所 A型ボツリヌス毒素中和組成物及びヒト抗a型ボツリヌス毒素抗体
EP2716763A3 (en) 2008-04-29 2014-07-02 Monsanto Technology LLC Genes and uses for plant enhancement
WO2010039750A2 (en) * 2008-10-01 2010-04-08 Monsanto Technology Llc Transgenic plants with enhanced agronomic traits
CA2742968C (en) * 2008-11-07 2020-06-09 Fabrus Llc Combinatorial antibody libraries and uses thereof
US20120117685A1 (en) 2009-02-27 2012-05-10 Wei Wu Isolated Novel Nucleic Acid and Protein Molecules from Soybeans and Methods of Using Thos Molecules
MX2012008108A (es) 2010-01-11 2012-10-03 Alexion Pharma Inc Biomarcadores de efectos de inmunomodulacion en seres humanos tratados con anticuerpos anti-cd200.
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
RU2636029C2 (ru) 2011-02-01 2017-11-17 Генмаб А/С Человеческие антитела и конъюгаты антитело-препарат против cd74
US20130102031A1 (en) * 2011-10-25 2013-04-25 Anaptysbio, Inc. Use of somatic hypermutation to create insertion and deletion mutations in vitro
US9175082B2 (en) * 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
WO2014036562A2 (en) * 2012-08-31 2014-03-06 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
CN106414500B (zh) 2013-11-07 2020-04-10 纪念斯隆-凯特琳癌症中心 抗-wt1/hla双特异性抗体
IL301714A (en) 2013-12-24 2023-05-01 Janssen Pharmaceutica Nv Antibodies and anti-VISTA fragments
GB201410520D0 (en) * 2014-06-12 2014-07-30 Univ London Queen Mary Antibody

Similar Documents

Publication Publication Date Title
JP2019512207A5 (cg-RX-API-DMAC7.html)
CN107405397B (zh) 抗tim-3抗体
JP2020501531A5 (cg-RX-API-DMAC7.html)
CN110891650A (zh) 制导和导航控制蛋白及其制造和使用方法
KR20180114218A (ko) 항-lag-3 항체
CN108337890A (zh) 新型pd-1免疫调节剂
JP2019524693A5 (cg-RX-API-DMAC7.html)
JP2021511818A (ja) Vista抗原結合性分子
JP2017535257A5 (cg-RX-API-DMAC7.html)
CN116948035A (zh) 多特异性抗体及其制备和使用方法
CN107428832A (zh) 抗pd‑l1抗体
JP2013506428A5 (cg-RX-API-DMAC7.html)
JP2017510251A (ja) 抗SIRPα抗体および二重特異性マクロファージ増強抗体
JP2018500014A5 (cg-RX-API-DMAC7.html)
CN117946278A (zh) 多特异性抗体及其制备和使用方法
CN111655286A (zh) 作为免疫调节剂的cd96结合剂
CN112292399A (zh) 抗cd27抗体及其用途
JP7418326B2 (ja) 二重特異性抗体並びにその製造方法及び使用方法
WO2021121373A1 (zh) 抗人程序死亡因子-1单克隆抗体
KR20210027254A (ko) Tim-3에 대한 항체 및 그의 용도
JP2016529213A5 (cg-RX-API-DMAC7.html)
Sandeep et al. Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics
AU2018370120A1 (en) Methods for selective expansion of d3 yd T-cell populations and compositions thereof
JP2020533002A5 (cg-RX-API-DMAC7.html)
TW202328196A (zh) 使用vista抗原結合分子的癌症之治療及預防